Search results
Results from the WOW.Com Content Network
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process.
Regardless of the presence of malignancy, patients with symptomatic neurocutaneous melanosis generally have a poor prognosis with few treatment options. [4] The pathogenesis of neurocutaneous melanosis is believed to be related to the abnormal postzygotic development of melanoblasts and mutations of the NRAS gene. [5]
Tonic seizures, with movements of the leg, arm or face, refractory to treatment with anti-epileptic drugs may precede the disorders, and should lead to testing for anti-LGI1 antibodies. [ 7 ] Anti-CASPR2 nervous system manifestations : Patients with anti-CASPIR2 antibodies develop symptoms from the CNS and/or the peripheral nervous system. [ 8 ]
It can be further categorized in three subtypes: antibody-negative probable autoimmune encephalitis, autoimmune limbic encephalitis and acute disseminated encephalomyelitis. [4] One therapeutic approach to seronegative autoimmune encephalitis is using as a first-line treatment corticosteroids and intravenous immunoglobulin. [4]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The antibody can be used to diagnose Alzheimer's disease. For premium support please call: 800-290-4726 more ways to reach us
Micrograph of a GFAP immunostained section of a brain tumour.. In biochemistry, immunostaining is any use of an antibody-based method to detect a specific protein in a sample. . The term "immunostaining" was originally used to refer to the immunohistochemical staining of tissue sections, as first described by Albert Coons in 1941.
[8] [9] Treatment also had to be tailored to each individual patient, which was impracticable in routine clinical settings. [citation needed] Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are distinguished by suffixes on their name. [citation needed]